Answers are grounded in this paper and cite their sources.
This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.
No takes yet. Share an insight, caveat, or question.
Beck et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: